| Literature DB >> 31998451 |
Parastoo Rezaee1, Rouha Kasra Kermanshahi1, Tahereh Falsafi1.
Abstract
OBJECTIVES: Treatment of Helicobacter pylori infection by common drugs may be associated with several problems such as antimicrobial resistance to commonly used antibiotics and side effects of employed drugs. Therefore, exploration of non-chemical compounds which are safer than chemical ones is becoming important as an alternative therapy. The purpose of this study was to evaluate the effects of lactic acid bacteria (LAB) against clinical strains of H. pylori.Entities:
Keywords: Antibacterial effect; CFS; Epithelial cell line; H. pylori; LAB; Urease activity
Year: 2019 PMID: 31998451 PMCID: PMC6885385 DOI: 10.22038/ijbms.2019.33321.7953
Source DB: PubMed Journal: Iran J Basic Med Sci ISSN: 2008-3866 Impact factor: 2.699
Helicobacter pylori strains used in this study
|
| Antibiotic resistance profile | Sex-age- pathalogy | ||
|---|---|---|---|---|
| Resistance | Rensitive | Male-14-CG | ||
| 1 | HP1 | Met, Cly, Amox, Amp, FR, E, ATH | TE, CIP, CRO, CFM | Female-13-CG |
| 2 | hp13 | Met, Cly, Amox, Amp, TE, E, ATH | CIP, FR, CRO, CFM | Female-62-CG |
| 3 | HP70 | Met, Cly, Amox, Amp, TE, E, ATH | FR, CRO, CFM | Female-24-CG |
| 4 | HP153 | Met, Cly, Amox, Amp, TE, FR, E, ATH, CFM | CIP,CRO | Female-4-CG |
| 5 | 157 | Met, Cly, Amox, Amp, FR, E, ATH | TE, CIP, CRO, CFM | Male-9-CG |
| 6 | 23F | Met, Cly, Amox, Amp, TE, CIP, E, CFM, CRO, FR, ATH | - | CG |
| 7 | AS923 | Met, Cly, Amox, Amp, CIP, E, FR, E, ATH | TE, CRO, CFM | Male-4-CG |
| 8 | PR | Met, Cly, Amox, Amp, TE, CIP, CFM, CRO, FR, E | ATH | Male-14-CG |
CG: Chronic Gastritis
Amo: Amoxicillin (25 µg/disk), TE: Tetracycline (30 µg/disk), Amp: Ampicillin (10 µg/disk), CIP: Ciprofloxacin (5 µg/disk), ATH: Azithromycin (15 µg/disk), E: Erythromycin (15 µg/disk), CRO: Ceftriaxone (30 µg/disk), CFM: Cefixime (5 µg/disk), FR: Furazolidone (100 µg/disk), Met: Metronidazole (5 µg/disk), Cly: Clarithromycin (15 µg/disk)
Figure 1(A-H) Count of Helicobacter pylori strains (log10 CFU/ml) in presence of cell free supernatant (CFS) of lactobacillus bacteria and lactobacillus bacteria alone after 48 hr incubation at 37 °C (equal volume, initial concentration of bacteria were 108 CFU/ml). (1: MRS Broth Medium; 2: Lactobacillus acidophilus ATCC 4356; 3: Lactobacillus rhamnosus ATCC 7469; 4: Lactobacillus reuteri ATCC 23272; 5: Lactobacillus fermentum ATCC 9338; 6: Lactobacillus plantarum ATCC 8014; 7: Lactobacillus casei ATCC 39392)
Reduction (%) of Helicobacter pylori in presence of Cell Free Supernatant (CFS) & lactobacillus bacteria
| LAB | Strains of | |
|---|---|---|
| CFS | LAB | |
|
| 100% (8) | 25% (2) |
|
| 100 %(8) | 25% (2) |
|
| 100 %(8) | 62.5% (5) |
|
| 50% (4) | 25% (2) |
|
| 75 %(6) | 37.5% (3) |
|
| 100 %(8) | 62.5% (5) |
Figure 2Effect of lactobacilli cell free supernatant (CFS) (30% concentration) on urease activity of Helicobacter pylori strains by measuring the absorbance of ammonium at 550 nm after 120 min
Figure 3Number (log10 CFU/ml) of adherent Helicobacter pylori on AGS cell line in the presence and in absence of lactobacillus bacteria after 3 hr incubation at 37 °C. Data represent mean±standard deviation (SD) from 3 independent experiments (error bar)